CARsgen Therapeutics Holdings (HKSE:02171) Debt-to-Equity : 0.05 (As of Dec. 2023)

View and export this data going back to 2021. Start your Free Trial

What is CARsgen Therapeutics Holdings Debt-to-Equity?

CARsgen Therapeutics Holdings's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was HK$16.14 Mil. CARsgen Therapeutics Holdings's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was HK$77.08 Mil. CARsgen Therapeutics Holdings's Total Stockholders Equity for the quarter that ended in Dec. 2023 was HK$1,970.66 Mil. CARsgen Therapeutics Holdings's debt to equity for the quarter that ended in Dec. 2023 was 0.05.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for CARsgen Therapeutics Holdings's Debt-to-Equity or its related term are showing as below:

HKSE:02171' s Debt-to-Equity Range Over the Past 10 Years
Min: -0.12 Med: 0.05 Max: 0.11
Current: 0.05

During the past 5 years, the highest Debt-to-Equity Ratio of CARsgen Therapeutics Holdings was 0.11. The lowest was -0.12. And the median was 0.05.

HKSE:02171's Debt-to-Equity is ranked better than
72.97% of 1069 companies
in the Biotechnology industry
Industry Median: 0.15 vs HKSE:02171: 0.05

CARsgen Therapeutics Holdings Debt-to-Equity Historical Data

The historical data trend for CARsgen Therapeutics Holdings's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CARsgen Therapeutics Holdings Debt-to-Equity Chart

CARsgen Therapeutics Holdings Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Equity

-0.12

-0.06

0.11

0.05

CARsgen Therapeutics Holdings Semi-Annual Data
	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Debt-to-Equity	Get a 7-Day Free Trial				0.11	0.12	0.05	0.05	0.05

Competitive Comparison of CARsgen Therapeutics Holdings's Debt-to-Equity

For the Biotechnology subindustry, CARsgen Therapeutics Holdings's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

CARsgen Therapeutics Holdings's Debt-to-Equity Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, CARsgen Therapeutics Holdings's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where CARsgen Therapeutics Holdings's Debt-to-Equity falls into.

CARsgen Therapeutics Holdings Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

CARsgen Therapeutics Holdings's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(16.135	+	77.076)	/	1970.661
	=	0.05

CARsgen Therapeutics Holdings's Debt to Equity Ratio for the quarter that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(16.135	+	77.076)	/	1970.661
	=	0.05

CARsgen Therapeutics Holdings (HKSE:02171) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

CARsgen Therapeutics Holdings Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of CARsgen Therapeutics Holdings's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

CARsgen Therapeutics Holdings (HKSE:02171) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CARsgen Therapeutics Holdings Ltd (HKSE:02171) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

CRTHF:USA

Address

No. 388 Yindu Road, Building 12, CMC Preparation Center, Xuhui District, Shanghai, CHN

Website

https://www.carsgen.com

CARsgen Therapeutics Holdings Ltd is a global clinical-stage biopharmaceutical company discovering, researching and developing cell therapies in the People's Republic of China and the United States of America.

Executives

Guo Bingsen	2401 A concert party to an agreement to buy shares
Guo Huaqing	2101 Beneficial owner
Li Zonghai	2401 A concert party to an agreement to buy shares
Wang Huamao	2401 A concert party to an agreement to buy shares
Gic (ventures) Pte. Ltd.	2201 Interest of corporation controlled by you
Gic Private Limited	2201 Interest of corporation controlled by you
Gic Special Investments Private Limited	2102 Investment manager
Yang Zhi	2201 Interest of corporation controlled by you
Prowell Ventures Pte Ltd	2201 Interest of corporation controlled by you
Bvcf Realization Fund, L.p.	2201 Interest of corporation controlled by you
Bvcf Realization Fund Gp, Ltd.	2201 Interest of corporation controlled by you
Zhejiang Jolly Healthcare Investment Management Limited	2201 Interest of corporation controlled by you
Applied Biomaterial Ltd.	2201 Interest of corporation controlled by you
Zhejiang Jolly Pharmaceutical Co., Ltd.	2201 Interest of corporation controlled by you
Zhejiang Zuoli Innovation Medical Investment Management Co., Ltd.	2101 Beneficial owner

CARsgen Therapeutics Holdings (HKSE:02171) Headlines

No Headlines